Warning: mkdir(): Permission denied in /data/Websites/newwiki-mpm/fuel/core/classes/log.php on line 122

Warning!

ErrorException [ Warning ]: mkdir(): Permission denied

COREPATH/classes/log.php @ line 122:

121:	
122:	mkdir($filepath, \Config::get('file.chmod.folders', 0777), true);
123:	umask($old);
FGF6 - Wiki-MPM

Search Results for: FGF6

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel CELSR1 cadherin EGF LAG seven-pass G-type receptor 1
Novel KLRC2 killer cell lectin like receptor C2
  • DAP12 interactions
  • DAP12 signaling
  • DAP12 signaling
FGFR1 fibroblast growth factor receptor 1
  • Signaling by activated point mutants of FGFR1
  • Signaling by FGFR1 in disease
  • Signaling by plasma membrane FGFR1 fusions
  • Palifermin
  • Sorafenib
  • Heparin
  • 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone
  • XL999
  • 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine
  • (E)-[4-(3,5-Difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol
  • 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Nintedanib
  • Fostamatinib
  • Erdafitinib
  • Pemigatinib
  • Selpercatinib
  • Pralsetinib
  • Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate
  • Hypogonadotropic hypogonadism; Kallmann syndrome (KAL)
  • Osteoglophonic dysplasia (OD); Osteoglophonic dwarfism (OGD)
  • Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome
FGFR2 fibroblast growth factor receptor 2
  • Signaling by FGFR2 amplification mutants
  • Activated point mutants of FGFR2
  • Signaling by FGFR2 in disease
  • Signaling by FGFR2 IIIa TM
  • Signaling by FGFR2 fusions
  • Palifermin
  • Thalidomide
  • Heparin
  • Sucrosofate
  • 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone
  • 4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Nintedanib
  • Foreskin fibroblast (neonatal)
  • Foreskin keratinocyte (neonatal)
  • Fostamatinib
  • Erdafitinib
  • Pemigatinib
  • Selpercatinib
  • Pralsetinib
  • Gastric cancer
  • Lacrimo-auriculo-dento-digital syndrome (LADD); Levy-Hollister syndrome
  • Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome
FGFR3 fibroblast growth factor receptor 3
  • Signaling by activated point mutants of FGFR3
  • FGFR3 mutant receptor activation
  • t(4;14) translocations of FGFR3
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • XL999
  • Pazopanib
  • Ponatinib
  • Lenvatinib
  • Nintedanib
  • Fostamatinib
  • Erdafitinib
  • Pemigatinib
  • Selpercatinib
  • Bladder cancer
  • Multiple myeloma
  • Lacrimo-auriculo-dento-digital syndrome (LADD); Levy-Hollister syndrome
  • Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome
  • FGFR3-related short limb skeletal dysplasias, including: Achondroplasia; Hypochondroplasia; Thanatophoric dysplasia, type 1; Thanatophoric dysplasia, type 2; Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN)
  • CATSHL syndrome
FGFR4 fibroblast growth factor receptor 4
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • betaKlotho-mediated ligand binding
  • FGFR4 mutant receptor activation
  • FGFR4 ligand binding and activation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade; FGFR4
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR4 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Heparin
  • Ponatinib
  • Lenvatinib
  • Erdafitinib
  • Pemigatinib
NCALD neurocalcin delta
  • Activation of Ca-permeable Kainate Receptor

Page 1 out of 1 pages